Skip to content
value.today
Ideaya Biosciences, Inc. logo

Ideaya Biosciences, Inc.

Total raised
$111 M
2 rounds on record
Latest round
$94 M
Jan 2018
First round on record
Mar 2016
Today
Went public
See the company page

Ideaya Biosciences, Inc. is listed today as IDEAYA Biosciences, Inc.: market value, financials and filings are on its company page.

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Ideaya Biosciences, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jan 2018$94 MNo. 2$50 to $250 million

Ideaya Biosciences, Inc.: Raise no. 2, Jan 2018

Investors in this round

23 investors had bought by the notice of May 11, 2018: 23 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Ideaya Biosciences, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$94 M of $94 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jeffrey P. Hager · Executive Officer
  • Michael P. Dillon · Executive Officer
  • Paul A. Stone · Executive Officer
  • Tim P. Smith · Executive Officer
  • Yujiro S. Hata · Director, Executive Officer
  • Brian Daniels · Director
  • Edward P. Hu · Director
  • Jeffrey S. Stein · Director
  • John D. Diekman · Director
  • Terry S. Rosen · Director
  • Thilo P. Schroeder · Director
  • Timothy S. Shannon · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Yujiro S. Hata, Chief Executive Officer. Source: SEC Form D, newest notice filed May 11, 2018. Read the notice at the SEC.

equitySEC
Mar 2016$17 MNo. 1$10 to $50 million

Ideaya Biosciences, Inc.: Raise no. 1, Mar 2016

Investors in this round

10 investors had bought by the notice of Aug 26, 2016: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Ideaya Biosciences, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$17 M of $46 M offered; $29 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Paul Stone · Executive Officer
  • Yujiro Hata · Executive Officer, Director
  • Jeffrey Stein · Director
  • John Diekman · Director
  • Terry Rosen · Director
  • Timothy Shannon · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The total amount sold in 13(b) includes the value of securities issued in exchange for cancellation of indebtedness of the Issuer to certain purchasers in the aggregate amount of $4,082,411.”

Signed by Mark V. Roeder, Secretary. Source: SEC Form D, newest notice filed Aug 26, 2016. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Ideaya Biosciences, Inc. chose not to state its revenue in its newest notice of a funding round (May 2018).

    SEC Form D · May 2018

  • The industry group it chose in its notices: Other.

    SEC Form D · May 2018

That is all the official record says: Ideaya Biosciences, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Ideaya Biosciences, Inc. are on record.

Investors#

6 named in official filings. Open an investor to see everything it has backed.

Investors in Ideaya Biosciences, Inc.
InvestorKindAmountRoundRoleSource
5AM Co-Investors IV, L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
5AM Partners IV, LLCFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
5AM Ventures IV, L.P.Venture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Alexandria Venture Investments, LLCVenture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Canaan Partners X LLCFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Canaan X L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2019)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 23 investors.

Largest shareholders today

Institutions holding IDEAYA Biosciences, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Ideaya Biosciences, Inc.
NameRoleNamed in
Jeffrey P. HagerExecutive officerMay 2018
Michael P. DillonExecutive officerMay 2018
Paul A. StoneExecutive officerMay 2018
Tim P. SmithExecutive officerMay 2018
Yujiro S. HataExecutive officerMay 2018
Paul StoneExecutive officerAug 2016
Yujiro HataExecutive officerAug 2016
Brian DanielsDirectorMay 2018
Edward P. HuDirectorMay 2018
Jeffrey S. SteinDirectorMay 2018
John D. DiekmanDirectorMay 2018
Terry S. RosenDirectorMay 2018
Thilo P. SchroederDirectorMay 2018
Timothy S. ShannonDirectorMay 2018
Yujiro S. HataDirectorMay 2018
Jeffrey SteinDirectorAug 2016
John DiekmanDirectorAug 2016
Terry RosenDirectorAug 2016
Timothy ShannonDirectorAug 2016
Yujiro HataDirectorAug 2016

About

Company in South San Francisco, United States.

Went public since 2019. Its SEC number is that of a company listed on a stock exchange.